Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EPS (Basic) (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed EPS (Basic) for 7 consecutive years, with $0.4 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 54.02% to $0.4 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.76 through Dec 2025, up 7.81% year-over-year, with the annual reading at $2.76 for FY2025, 7.81% up from the prior year.
  • EPS (Basic) hit $0.4 in Q4 2025 for Harmony Biosciences Holdings, down from $0.88 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.48 in Q3 2022 to a low of -$0.17 in Q3 2021.
  • Historically, EPS (Basic) has averaged $0.56 across 5 years, with a median of $0.53 in 2023.
  • Biggest five-year swings in EPS (Basic): crashed 76.65% in 2021 and later soared 970.59% in 2022.
  • Year by year, EPS (Basic) stood at $0.39 in 2021, then soared by 110.26% to $0.82 in 2022, then plummeted by 43.9% to $0.46 in 2023, then surged by 89.13% to $0.87 in 2024, then plummeted by 54.02% to $0.4 in 2025.
  • Business Quant data shows EPS (Basic) for HRMY at $0.4 in Q4 2025, $0.88 in Q3 2025, and $0.69 in Q2 2025.